During the clinical development program, 3,315 women (vaccine = 1,657 vs. placebo = 1,658) reported at least one pregnancy.
Kliinilise arenguprogrammi jooksul teatati vähemalt ühest rasedusest 3315 naisel (vaktsiin = 1657 vs platseebo = 1658).